Antigen-binding molecules that specifically bind to CD19, CD20, and CD3 and their pharmaceutical uses
TW202641861APending Publication Date: 2026-10-16JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW115100936
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-01-10
- Filing Date
- 2026-01-09
- Publication Date
- 2026-10-16
Smart Images
Figure TWG2TA001080905_001 
Figure TWG2TA001080905_002
Abstract
This disclosure relates to antigen-binding molecules that specifically bind to CD19, CD20, and CD3, and their pharmaceutical uses. Specifically, this disclosure relates to the use of trispecific antibodies that specifically bind to CD19, CD20, and CD3 in the preparation of medicaments for the treatment of cancer and autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art